DEN-181

Drug Profile

DEN-181

Alternative Names: Curcusome-RA; CurcusomeTM-RA; DEN181

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator University of Queensland
  • Developer Dendright
  • Class Anti-inflammatories; Immunotherapies
  • Mechanism of Action Immunosuppressants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Research Type 1 diabetes mellitus

Most Recent Events

  • 05 Jan 2017 Janssen Biotech in collaboration with Dendright plans a phase I trial for Rheumatoid arthritis in Australia
  • 07 Apr 2016 Tolerizing immonutherapy - Dendright is available for licensing as of 07 Apr 2016. http://www.dendright.com.au/content/investment-and-partnering
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top